CANCER LETTERS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2023-03-05 1231eb1dm07(暂无昵称) 来自广东省

偏重的研究方向：肿瘤
经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了

33 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2023-11-08 ms3000001768645493 来自天津

大神们，明年影响因子有预测吗

99 0

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2023-11-02 1459fafam67暂无昵称来自湖北省

请问下各位，字数超了，可以把部分方法内容放附件吗？

51 0

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2023-11-02 1de85404m20(暂无匿称) 来自广东省

各位大佬，大修一般肯定还会再次送审吗，着急呀

18 0

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2022-03-23 ms5000000107225319

审稿速度:1.0
偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学
经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣

198 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2023-09-04 Riverswide 来自江苏省

偏重的研究方向：肿瘤
经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思

38 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2023-10-18 ms6000001495647481 来自陕西省

偏重的研究方向：DNA损伤;肿瘤
经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收

27 0

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2023-10-18 llllkn 来自浙江省

请问后来怎么样了？

17 0

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2023-08-15 biocell160 来自贵州省

8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！

27 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2117776, encodeId=99d2211e7762a, content=偏重的研究方向：肿瘤 经验分享：请问各位大佬with editor 8天之后就decision in process是不是意味着被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=428e2384755, createdName=1231eb1dm07(暂无昵称), createdTime=Sun Mar 05 19:46:35 CST 2023, time=2023-03-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2167387, encodeId=7469216e3871d, content=大神们，明年影响因子有预测吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ebc8131350, createdName=ms3000001768645493, createdTime=Wed Nov 08 13:33:18 CST 2023, time=2023-11-08, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2166215, encodeId=89e0216621519, content=请问下各位，字数超了，可以把部分方法内容放附件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d2e5075184, createdName=1459fafam67暂无昵称, createdTime=Thu Nov 02 00:21:02 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2166224, encodeId=167f216622487, content=各位大佬，大修一般肯定还会再次送审吗，着急呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=1de85404m20(暂无匿称), createdTime=Thu Nov 02 01:37:52 CST 2023, time=2023-11-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1205369, encodeId=eae312053696d, content=审稿速度:1.0 偏重的研究方向：DNA损伤;小细胞肺癌;肿瘤生物学 经验分享：2022年2月26日投稿，2月28日让修改格式补充审稿人信息，3月8日under review，3月15日又under review，不知道为啥日期变了状态不变，现在3月23日了还没有消息，很焦急😫，会持续给大家更新状态的，祝我好运小修接收吧😣😣😣, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=198, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=ms5000000107225319, createdTime=Wed Mar 23 21:32:56 CST 2022, time=2022-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2156030, encodeId=b7f32156030f8, content=偏重的研究方向：肿瘤 经验分享：08.30 submitted to journal 08.31改格式重投 09.01 with editor 09.02with editor时间变了不知道是什么意思, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJicNxaibzicFd3zQMibV0sw9miaRu5RAPg2QncI2aFOzIsAPqHklCxrR7nSQE8Q7wUbopkgdEQK7K7kTQ/132, createdBy=5f995124551, createdName=Riverswide, createdTime=Mon Sep 04 14:21:03 CST 2023, time=2023-09-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2163578, encodeId=eb0c21635e868, content=偏重的研究方向：DNA损伤;肿瘤 经验分享：7月4日投稿，7月20日一审大修，9月15日修回，10月6日接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dbe8158611, createdName=ms6000001495647481, createdTime=Wed Oct 18 16:17:24 CST 2023, time=2023-10-18, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2163452, encodeId=1c4e216345232, content=请问后来怎么样了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLpoPPhtQvTy6ZNyQ95jvIy5Mg0FETNLcMqjrfaRfjvTAUCiaZmPHFBcHuhOZwcxMtUoINWicGI64Sw/132, createdBy=d64b5284505, createdName=llllkn, createdTime=Wed Oct 18 06:52:38 CST 2023, time=2023-10-18, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2152863, encodeId=cf2d2152863ef, content=8.9投，8.10改格式，8.11with editor，8.12decision in process，等着宣判，酸爽！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/94RcfbZgzvtj5txdt4ia4g80zFHGhkVkUnKoQc0E9WF4hZ8XdN5UlcGiabmqTRiarpOm2Es15NopPfKeVicJIsBtEA/132, createdBy=ce481603107, createdName=biocell160, createdTime=Tue Aug 15 13:09:33 CST 2023, time=2023-08-15, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=906691, encodeId=70e8906691dc, content=大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position)., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=797281934, createdName=gf296144988, createdTime=Thu Dec 10 13:23:53 CST 2020, time=2020-12-10, status=1, ipAttribution=)]

2020-12-10 gf296144988

大家好，请问这个Cover letter 是怎么弄呢，不是很懂，麻烦有知道的能否解答一下，多谢了。The Cover Letter must be on Institution Letterhead and it must be complete with all information (Department, Laboratory, phone number, email, academic title, position).

182 8

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务